ライフサイエンスコーパス: influenza vaccination

1 ctiveness of HD influenza vaccination (vs SD influenza vaccination).

2 influenza-positive HCWs with fever and prior influenza vaccination.

3 After 21 d, subjects received the seasonal influenza vaccination.

4 r (aged >/=65 years) adults before and after influenza vaccination.

5 influenza, had lower odds of having received influenza vaccination.

6 recipients before and 1 month after seasonal influenza vaccination.

7 sponses get boosted in humans after seasonal influenza vaccination.

8 ple roles in inducing protective immunity to influenza vaccination.

9 ng the importance of primary prevention with influenza vaccination.

10 ression on recall T- and B-cell responses to influenza vaccination.

11 in depth both at baseline and in response to influenza vaccination.

12 is several times greater than that following influenza vaccination.

13 ollowing vaccinations of any kind, including influenza vaccination.

14 ous estimates of the disorder after seasonal influenza vaccination.

15 gnificantly influences the human response to influenza vaccination.

16 ssociation of GBS after 2009 monovalent H1N1 influenza vaccination.

17 nses to prophylactic vaccinations, including influenza vaccination.

18 n and memory B cells isolated after seasonal influenza vaccination.

19 to live-attenuated or trivalent-inactivated influenza vaccination.

20 ung and elderly individuals before and after influenza vaccination.

21 arly vaccinations with trivalent-inactivated influenza vaccination.

22 peptides and expansion of one of these after influenza vaccination.

23 ose subjects aged >/= 65 years, 78% received influenza vaccination.

24 ction during pregnancy and the importance of influenza vaccination.

25 After 21 d, all subjects received an influenza vaccination.

26 titers of hemagglutination inhibition after influenza vaccination.

27 are was associated with an increased rate of influenza vaccination.

28 ing is a novel, scalable approach to promote influenza vaccination.

29 mptoms and improved their immune response to influenza vaccination.

30 itamin D (25[OH]D), and humoral responses to influenza vaccination.

31 at baseline and at 2, 6, and 12 weeks after influenza vaccination.

32 elicited a de novo immune response following influenza vaccination.

33 d from 60 SLE patients at baseline and after influenza vaccination.

34 pronounced among patients with prior season influenza vaccination.

35 mount protective immunological responses to influenza vaccination.

36 lar immune reactivity in subjects undergoing influenza vaccination.

37 n coincident temporal association with novel influenza vaccination.

38 % protein) in an established murine model of influenza vaccination.

39 r in inducing protective immune responses to influenza vaccination.

40 e of stillbirth following seasonal trivalent influenza vaccination.

41 dy design, in assessing the effectiveness of influenza vaccination.

42 on therapy can mount effective responses to influenza vaccination.

43 hanisms underlying differential responses to influenza vaccination.

44 nd T-cell responses before and 4 weeks after influenza vaccination.

45 ation could also enhance immune responses to influenza vaccination.

46 ffect of L. casei 431 on immune responses to influenza vaccination.

47 All children had a history of prior influenza vaccinations.

48 za-infected HCWs, 20 had previously received influenza vaccination, 18 had declined the vaccine, and

49 visit (60.9% vs. 55.2%; P < .001) but not an influenza vaccination (22.1% vs. 21.5%; P = .70).

50 In vivo after influenza vaccination, activated CD4 T cells from elderl

51 ed hazard ratio, 1.04; 95% CI, 0.68-1.58) or influenza vaccination (adjusted hazard ratio, 1.10; 95%

52 All influenza vaccinations administered between 1 August and

53 The efficacy of seasonal influenza vaccination against 2009 pandemic influenza A(

54 Annual influenza vaccinations aim to protect against seasonal i

55 We defined influenza vaccination, all-cause mortality, and potentia

56 nationwide sample of Medicare beneficiaries, influenza vaccination among adults aged 18-64 years was

57 the need for additional studies on maternal influenza vaccination and autism.

58 n interferon transcriptional signature after influenza vaccination and by an inflammation signature a

59 fic antibodies, as well as macrophages, upon influenza vaccination and challenge.

60 t circulating TFR frequencies increase after influenza vaccination and correlate with anti-flu Ab res

61 conclude that bias is inherent in studies of influenza vaccination and death among elderly patients.

62 o guide and prioritize interventions such as influenza vaccination and HIV prevention in low- and mid

63 lecular events that take place in vivo after influenza vaccination and in the development of better p

64 ral strains could reduce the need for yearly influenza vaccination and increase our preparedness for

65 We analyzed influenza vaccination and influenza severity using Influ

66 sought to determine the association between influenza vaccination and major adverse vascular events

67 There were no cases of recurrent GBS after influenza vaccination and none within 6 weeks after any

68 Recent receipt of seasonal influenza vaccination and older age were associated with

69 fluenza pandemic and of vigorously promoting influenza vaccination and other prevention efforts.

70 n the analyses revealed associations between influenza vaccination and outcome during noninfluenza se

71 dies have evaluated the relationship between influenza vaccination and pneumonia, a serious complicat

72 sights regarding the serological response to influenza vaccination and raise questions about the adde

73 reafter, L. casei 431) on immune response to influenza vaccination and respiratory symptoms in health

74 on days 0 to 1, adjusted for age group, past influenza vaccination and simultaneous receipt of select

75 Influenza vaccination and statin prescription statuses o

76 ntigen, and there was no association between influenza vaccination and the outcome (adjusted OR, 0.96

77 onditions should be considered when planning influenza vaccination and treatment strategies.

78 anging from 10% lower for those who received influenza vaccinations and >or=2 A1c tests, to 43% lower

79 d pressure screening, cholesterol screening, influenza vaccination, and annual dental visit.

80 eceiving chemotherapy are able to respond to influenza vaccination, and because this intervention is

81 nd 9 lung transplant recipients who received influenza vaccination, and from 20 healthy unvaccinated

82 atment, adjusting for underlying conditions, influenza vaccination, and pregnancy trimester.

83 sease, were more likely to have received the influenza vaccination, and were less likely to report fe

84 ce; cardiovascular, lung, and renal disease; influenza vaccination; and antiviral administration.

85 larly, the serological responses to seasonal influenza vaccination are also determined largely by non

86 dies in which the fetal benefits of maternal influenza vaccination are evaluated by estimating detect

87 ts suggest that allergic reactions following influenza vaccination are not necessarily related to egg

88 aluate the benefits to the fetus of maternal influenza vaccination because the causal benefit of vacc

89 Pandemic H1N1 2009 influenza vaccination began in week 43 of 2009 (Oct 21,

90 The adjusted odds ratio of prior influenza vaccination between cases and controls was 0.4

91 significant benefit according to adherence, influenza vaccination, body mass index, or baseline vita

92 re, Thailand and Vietnam) had guidelines for influenza vaccination but only two were consistent with

93 on the components of the immune response to influenza vaccination but reduced the duration of upper

94 e the immune response of elderly subjects to influenza vaccination, but its effectiveness has not yet

95 recommendations and should encourage annual influenza vaccination by offering influenza vaccination

96 ark from pregnancies overlapping the A(H1N1) influenza vaccination campaign in Denmark, from November

97 These include the 2009-10 H1N1 pandemic influenza vaccination campaign, renewed attention to the

98 HCP influenza vaccination can enhance patient safety.

99 Our findings newly demonstrate that influenza vaccination can have a significant impact on t

100 Neighborhood-level analyses of influenza vaccination can identify the characteristics o

101 Some studies suggest that maternal influenza vaccination can improve birth outcomes.

102 Influenza vaccinations can protect against disease but m

103 During the acute response to influenza vaccination, CD19(pos), CD19(low), and CD19(ne

104 r physicians and the percentage who received influenza vaccination, cholesterol screening, colorectal

105 ad impaired production of antibody following influenza vaccination compared to WT mice (mean antibody

106 ureus exhibited a reduced immune response to influenza vaccination compared with noncolonized partici

107 re to circulating human influenza viruses or influenza vaccination confers immunity to H7N9 strains.

108 sed antibody response compared with standard influenza vaccination consisting of a single dose.

109 examined the association between county-wide influenza vaccination coverage among 520 229 younger adu

110 Increasing influenza vaccination coverage among young children and

111 Targeted efforts are needed to improve influenza vaccination coverage and reduce disparities.

112 Influenza vaccination coverage derived from data from th

113 potential for self-administration can expand influenza vaccination coverage in developing countries.

114 At 7 d after inactivated influenza vaccination, cTfh correlated with influenza va

115 Influenza vaccination dates were confirmed by medical re

116 quently underperform in response to seasonal influenza vaccination, despite virologic control of HIV.

117 Influenza vaccination during 2013-14 influenza season at

118 udy has investigated the association between influenza vaccination during pregnancy and ASD.

119 Using an RCT as a vaccine probe, influenza vaccination during pregnancy decreased all-cau

120 Influenza vaccination during pregnancy does not appear t

121 Despite strong evidence that maternal influenza vaccination during pregnancy is safe, uptake o

122 cination during pregnancy is safe, uptake of influenza vaccination during pregnancy remains low.

123 (0.7%) mothers and 45 231 (23%) received an influenza vaccination during pregnancy.

124 niors (65+ years) after high-risk groups for influenza vaccination during times of limited vaccine su

125 niors (65+ years) after high-risk groups for influenza vaccination during times of limited vaccine su

126 Novel delivery methods can render influenza vaccination easier and more acceptable by the

127 penic hematological conditions and uptake of influenza vaccination encouraged to further reduce the n

128 n suggests that evaluating immunogenicity of influenza vaccination exclusively by hemagglutination in

129 n Academy of Pediatrics now recommend annual influenza vaccination for all children 6 months through

130 e data support increased access to HAART and influenza vaccination for HIV-infected adults.

131 systematic review and meta-analysis assesses influenza vaccination for immunocompromised patients in

132 ributed to an extension of target groups for influenza vaccination for the 2010/2011 season.

133 be considered by policy makers recommending influenza vaccinations for elderly people.

134 splantation for annual trivalent inactivated influenza vaccination greater than 3 to 6 months post-ki

135 ategies, but little information exists about influenza vaccination guidelines and vaccine sales.

136 Influenza vaccination guidelines have recommended that p

137 The effectiveness of trivalent influenza vaccination has been confirmed in several stud

138 d a history of GBS within 6 weeks of a prior influenza vaccination if they are not at high risk of se

139 not (n = 29) immediately before inactivated influenza vaccination (IIV), 7 d after vaccination, and

140 fication of receipt of trivalent inactivated influenza vaccination (IIV-3).

141 No significant difference regarding the influenza-vaccination immune response was shown.

142 n a randomized, controlled trial of seasonal influenza vaccination in 773 children aged 6-17 years, w

143 e for circulating Tfh cells (cTfh) following influenza vaccination in adults, but cTfh have not been

144 ntigen-specific IL-21(+) CD4(+) T cells upon influenza vaccination in adults.

145 ological evidence base for continuing annual influenza vaccination in adults.

146 al decades on how to approach the subject of influenza vaccination in children with egg allergy.

147 ly taken a conservative approach of avoiding influenza vaccination in egg-allergic patients.

148 teady-state and during the acute response to influenza vaccination in healthy donors, we identify the

149 ted with decreased antibody production after influenza vaccination in healthy human volunteers (P=0.0

150 (SNPs) in the HO-1 gene and the response to influenza vaccination in healthy humans.

151 ibe molecular signatures driving immunity to influenza vaccination in humans.

152 thors analyzed rates of 2009 pandemic A/H1N1 influenza vaccination in Montreal, Quebec, Canada, using

153 proved understanding of the ADCC response to influenza vaccination in older adults is required.

154 The role of seasonal influenza vaccination in pandemic influenza A H1N1 disea

155 ential strategies to improve the efficacy of influenza vaccination in patients with cancer, such as t

156 re is uncertainty about the effectiveness of influenza vaccination in persons with asthma and its imp

157 s add to the evidence base for the safety of influenza vaccination in pregnancy.

158 risk of foetal loss associated with pandemic influenza vaccination in pregnancy.

159 tional study in Laos to assess the effect of influenza vaccination in pregnant women on birth outcome

160 We estimated the effectiveness of documented influenza vaccination in preventing laboratory-confirmed

161 The effectiveness of 2010-2011 influenza vaccination in preventing laboratory-confirmed

162 aphic factors that influence the response to influenza vaccination in SLE patients with a broad range

163 re associated with low antibody responses to influenza vaccination in SLE patients.

164 cumulative proportions of persons reporting influenza vaccination in the 2004-2005 through 2010-2011

165 icate that the inferior antibody response to influenza vaccination in the elderly is primarily due to

166 been implicated in poor Ab responsiveness to influenza vaccination in the elderly, most of whom are C

167 Recent studies suggest that influenza vaccination in the previous season may influen

168 Maternal influenza vaccination in the second or third trimester w

169 isk among children whose mothers received an influenza vaccination in their first trimester, but the

170 and meta-analyses to assess the evidence for influenza vaccination in this group, and we report our r

171 Safety and immunogenicity data of seasonal influenza vaccination in transplanted patients (Tps) are

172 public health agency initiated school-based influenza vaccination in two Wisconsin elementary school

173 .77, p = 0.001), and 66% compared to 59% had influenza vaccinations in the past year (odds ratio 1.35

174 Recent studies have suggested that influenza vaccination increases the risk of noninfluenza

175 ng evidence that reduced VE after sequential influenza vaccination is a real phenomenon.

176 Although antenatal influenza vaccination is an important public health inte

177 We propose a radical change in the way influenza vaccination is approached, in which a recombin

178 CD4 T cell formation following cold-adapted influenza vaccination is boosted when Ag is administered

179 Influenza vaccination is less effective in elderly as co

180 Humoral response to influenza vaccination is not correlated with baseline BL

181 infection history in targeting and promoting influenza vaccination is predicted to be a highly effect

182 Although influenza vaccination is recommended for all adults annu

183 R, a booster strategy 5 weeks after standard influenza vaccination is safe and effective and induces

184 Influenza vaccination is safe even in children with hist

185 Influenza vaccination is the most effective means for di

186 Influenza vaccination is the primary approach to prevent

187 th maternal and infant morbidity, and annual influenza vaccination is warranted.

188 sequencing to dynamically track responses to influenza vaccination, Jackson et al. find evidence of c

189 For persons with asthma, influenza vaccination may be effective in both reducing

190 Influenza vaccination may benefit young children and HIV

191 observational studies suggest that previous influenza vaccination may influence the immunogenicity a

192 from some recent studies have suggested that influenza vaccination might also prevent adverse pregnan

193 Some studies suggest that influenza vaccination might be protective against severe

194 0 years ago, it was observed that sequential influenza vaccination might lead to reduced vaccine effe

195 Unlike antibodies elicited by annual influenza vaccinations, most neutralizing antibodies ind

196 an OVA immunization model and a preclinical influenza vaccination mouse model.

197 Our analyses suggest that influenza vaccinations not only prevent infection agains

198 suggests that the large fetal benefits from influenza vaccination observed in epidemiologic studies

199 BS cases' occurring during the 6 weeks after influenza vaccination of 45 million persons, an 8.8-fold

200 The available evidence suggests that influenza vaccination of children confers indirect prote

201 will better inform decision making regarding influenza vaccination of elderly adults.

202 Influenza vaccination of healthcare personnel (HCP) is r

203 Many national guidelines recommend annual influenza vaccination of immunocompromised patients, alt

204 dy evaluated the effectiveness of postpartum influenza vaccination of mothers and household members i

205 formed to determine the efficacy of antennal influenza vaccination of mothers plus pneumococcal conju

206 It is unknown whether influenza vaccination of nonelderly adults confers addit

207 Numerous studies support influenza vaccination of persons with egg allergy using

208 We explored the safety of influenza vaccination of pregnant women by linking Norwe

209 ore supports the continued recommendation of influenza vaccination of pregnant women.

210 Yet the impact of repeated annual influenza vaccination on both cross-reactive CD4+ and CD

211 We investigated the effect of influenza vaccination on disease severity in adults hosp

212 Our findings show a modest effect of influenza vaccination on disease severity.

213 network to further investigate the effect of influenza vaccination on influenza severity in adults ag

214 ough June 2012 to evaluate the effect of HCP influenza vaccination on mortality, hospitalization, and

215 pothesis, we examined the effect of seasonal influenza vaccination on NK cell function and phenotype

216 ecent reports of a negative impact of serial influenza vaccination on vaccine effectiveness (VE) rais

217 red memory T cell and Ab responses following influenza vaccination or infection, we investigated the

218 cells recalled from previous encounters with influenza vaccination or infection.

219 be concluded from these recent studies that influenza vaccination overall is of public health benefi

220 ere not correlated with humoral responses to influenza vaccination (P = 0.863), and BLyS levels incre

221 reinforce current recommendations for annual influenza vaccination, particularly those at greatest ri

222 mework to evaluate the cost-effectiveness of influenza vaccination policies in developing countries a

223 We evaluated such influenza vaccination policies through small-world conta

224 y individual providers on the basis of local influenza vaccination policy.

225 , and for therapeutic applications including influenza vaccination, polio vaccination, and diabetes a

226 These data are a step forward in making oral influenza vaccination possible.

227 italizations during 3 influenza seasons, and influenza vaccination prevented 61.2% of such hospitaliz

228 Influenza vaccination prevented influenza cases and hosp

229 Pneumococcal and influenza vaccinations prevented further transmission.

230 Maternal influenza vaccination prevents influenza illness in both

231 untry, which has yet to establish a national influenza vaccination program.

232 cility 90 days or more before commencing the influenza vaccination programme).

233 Influenza vaccination programmes around the world are st

234 Generally, influenza vaccination programmes have targeted individua

235 Consequently, most current influenza vaccination programs focus mainly on protectio

236 t activation of the RIG-I pathway along with influenza vaccination programs the innate immunity to in

237 To understand factors that may impact influenza vaccination programs, we developed a model to

238 target groups, timing, and cost of national influenza vaccination programs.

239 These data demonstrate that influenza vaccination promotes the prevalence of relevan

240 ghlights the need to assess whether seasonal influenza vaccination provides cross-protection against

241 emonstrate that the early B-cell response to influenza vaccination, quantified by the frequency of in

242 Antibody titers decrease with time following influenza vaccination, raising concerns that vaccine eff

243 However, the overall influenza vaccination rate remained low.

244 gh recommended by many and mandated by some, influenza vaccination rates among health care workers, e

245 With influenza vaccination rates in the United States recentl

246 nal and infant mortality/morbidity; however, influenza vaccination rates of pregnant women remain und

247 ons to vaccinate surgical inpatients against influenza, vaccination rates remain low in this populati

248 The outcome of interest is influenza vaccination receipt at free on-site clinics of

249 Annual influenza vaccination recommendations have been expanded

250 Influenza vaccination reduced influenza virus infection

251 Influenza vaccination reduced the risk of ARI associated

252 Effective annual influenza vaccination requires frequent changes in vacci

253 BCG vaccination prior to influenza vaccination results in a more pronounced incre

254 vel, physician office visits, and history of influenza vaccination (RR(9-17 years) = 1.20, RR(18-26 y

255 D are colonized with S aureus, intramuscular influenza vaccination should be given preference in thes

256 School-located influenza vaccination (SLV) programs can efficiently imm

257 ithout laboratory-confirmed influenza and by influenza vaccination status among subjects with influen

258 Influenza vaccination status was ascertained by vaccine

259 HCWs also reported symptoms and influenza vaccination status, and underwent temperature

260 had adequate respiratory samples, had known influenza vaccination status, and were community-dwellin

261 Influenza vaccination strategies have targeted elderly i

262 Universal influenza vaccination strategies should be capable of pr

263 Regional-specific influenza vaccination strategies would be optimal in Chi

264 DCC Abs and their potential role in improved influenza-vaccination strategies.

265 duction of memory T- and B-cell responses to influenza vaccination supports the recommendation to vac

266 in inducing protective antibody responses to influenza vaccination than CD4 T cell-deficient mice.

267 Finally, after influenza vaccination, the proportion of influenza-speci

268 to innate cytokines were also enhanced after influenza vaccination; this was associated with prolifer

269 took advantage of the pandemic 2009 A(H1N1) influenza vaccination to conduct a longitudinal integrat

270 accination, as well as pre-pandemic seasonal influenza vaccination to elucidate the effect of the adj

271 these findings reinforce the need for yearly influenza vaccination to prevent infection, and raise ne

272 age annual influenza vaccination by offering influenza vaccination to students at no cost.

273 introduce dissolving microneedle patches for influenza vaccination using a simple patch-based system

274 Effectiveness of 2014-2015 influenza vaccination varied by genetic group of influen

275 Effectiveness of 2014-2015 influenza vaccination varied by influenza A(H3N2) virus

276 Influenza vaccination, verified through record review.

277 We assessed the relative effectiveness of HD influenza vaccination (vs SD influenza vaccination).

278 Influenza vaccination was ascertained from physician bil

279 In inpatients, influenza vaccination was associated with a lower risk o

280 Influenza vaccination was associated with a lower risk o

281 Influenza vaccination was associated with a reduction in

282 During 2010-2011, influenza vaccination was associated with a significant

283 010-2011 and 2011-2012 US influenza seasons, influenza vaccination was associated with a three-quarte

284 l IgG or anti-Gal IgG, respectively, whereas influenza vaccination was associated with higher anti-no

285 Pandemic H1N1 2009 influenza vaccination was associated with protection aga

286 School-based influenza vaccination was associated with reduced absent

287 Although initial analyses suggest that influenza vaccination was associated with reduced risk o

288 Influenza vaccination was not associated with detection

289 Of patients for whom data was available, influenza vaccination was reported in 3289 (28.7%) of 11

290 tic regression analyses showed that maternal influenza vaccination was significantly associated with

291 trimester-specific analyses, first-trimester influenza vaccination was the only period associated wit

292 Influenza vaccination was verified in 35% (6/17) of adul

293 : Use of dissolvable microneedle patches for influenza vaccination was well tolerated and generated r

294 wing BCG vaccination, nonspecific effects of influenza vaccination were also observed, with modulatio

295 Effects of repeat influenza vaccination were consistent with the ADH and m

296 ancy modifies the humoral immune response to influenza vaccination will aid in maximizing vaccine eff

297 ctiveness of the Scottish pandemic H1N1 2009 influenza vaccination with a retrospective cohort design

298 The odds ratio of influenza vaccination within a 6-week interval prior to

299 All patients received influenza vaccination without an allergic reaction.

300 influenza vaccination without an allergic reaction.